Logo advanceCOR GmbH (to detail page)

advanceCOR GmbH

Personalised drug development for cardiovascular diseases up to proof of concept in patients.

Our network of clinical experts and excellent research allow the best possible combination of bench to bedside for new drugs.

advanceCOR has a lead project on stroke prevention. Revacept is a novel thrombosis inhibitor that has been shown to reduce the occurrence of strokes and other ischemic events in clinical trials. In contrast to all previous thrombosis drugs, where increased efficacy leads to increased bleeding, Revacept leads to less bleeding. We have thus solved a major dilemma in cardiology by developing an effective thrombosis inhibitor that safe for patient use.

In addition, we also offer a biomarker that can identify patients at high risk of bleeding and so treat vulnerable patients in a targeted and personalised manner. Treatment with Revacept will reduce the need for conventional thrombosis drug therapy.

We aim to out-licence our products after phase 2 of clinical development (proof of concept in man) and develop them jointly with pharmaceutical partners up to market launch.

WEBSITE